ISIS 3521: Began a Phase I dose-ranging study in up to 35-40 patients with a broad range of solid tumors.

Patients will be treated until their cancers progress or until there are drug-related toxicities. Cohorts of three patients each will start at 0.15 mg/kg and go up to 3 mg/kg or higher if there is no dose-limiting toxicity.

ISIP also plans another Phase I trial using a 24-hour infusion over 7-10 days once a month. ...